 | • レポートコード：MRC2-11QY14358 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は原発性胆汁性肝硬変薬のグローバル市場について調査・分析したレポートです。種類別（ブデソニド、FFP-104、GSK-2330672、MBX-8025、NGM-282、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別原発性胆汁性肝硬変薬の競争状況、市場シェア ・世界の原発性胆汁性肝硬変薬市場：種類別市場規模 2015年-2020年（ブデソニド、FFP-104、GSK-2330672、MBX-8025、NGM-282、その他） ・世界の原発性胆汁性肝硬変薬市場：種類別市場規模予測 2021年-2026年（ブデソニド、FFP-104、GSK-2330672、MBX-8025、NGM-282、その他） ・世界の原発性胆汁性肝硬変薬市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界の原発性胆汁性肝硬変薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米の原発性胆汁性肝硬変薬市場分析：米国、カナダ ・ヨーロッパの原発性胆汁性肝硬変薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの原発性胆汁性肝硬変薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の原発性胆汁性肝硬変薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの原発性胆汁性肝硬変薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AlbireoPharma、CymaBay Therapeutics, Inc.、Dr. Falk Pharma GmbH、Enanta Pharmaceuticals, Inc.、GlaxoSmithKline Plc、Intercept Pharmaceuticals, Inc.、Johnson & Johnson、MediGene AG、NGM Biopharmaceuticals, Inc.、Virobay Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Primary Biliary Cirrhosis Drug Market
The global Primary Biliary Cirrhosis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Primary Biliary Cirrhosis Drug Scope and Market Size
Primary Biliary Cirrhosis Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Primary Biliary Cirrhosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Primary Biliary Cirrhosis Drug market is segmented into
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others
Segment by Application, the Primary Biliary Cirrhosis Drug market is segmented into
Clinic
Hospital
Others
Regional and Country-level Analysis
The Primary Biliary Cirrhosis Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Primary Biliary Cirrhosis Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Primary Biliary Cirrhosis Drug Market Share Analysis
Primary Biliary Cirrhosis Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Primary Biliary Cirrhosis Drug business, the date to enter into the Primary Biliary Cirrhosis Drug market, Primary Biliary Cirrhosis Drug product introduction, recent developments, etc.
The major vendors covered:
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Intercept Pharmaceuticals, Inc.
Johnson & Johnson
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.
1 Study Coverage
1.1 Primary Biliary Cirrhosis Drug Product Introduction
1.2 Market Segments
1.3 Key Primary Biliary Cirrhosis Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type
1.4.2 Budesonide
1.4.3 FFP-104
1.4.4 GSK-2330672
1.4.5 MBX-8025
1.4.6 NGM-282
1.4.7 Others
1.5 Market by Application
1.5.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Primary Biliary Cirrhosis Drug Market Size, Estimates and Forecasts
2.1.1 Global Primary Biliary Cirrhosis Drug Revenue 2015-2026
2.1.2 Global Primary Biliary Cirrhosis Drug Sales 2015-2026
2.2 Global Primary Biliary Cirrhosis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Primary Biliary Cirrhosis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Primary Biliary Cirrhosis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Primary Biliary Cirrhosis Drug Competitor Landscape by Players
3.1 Primary Biliary Cirrhosis Drug Sales by Manufacturers
3.1.1 Primary Biliary Cirrhosis Drug Sales by Manufacturers (2015-2020)
3.1.2 Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Primary Biliary Cirrhosis Drug Revenue by Manufacturers
3.2.1 Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Primary Biliary Cirrhosis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Primary Biliary Cirrhosis Drug Revenue in 2019
3.2.5 Global Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Primary Biliary Cirrhosis Drug Price by Manufacturers
3.4 Primary Biliary Cirrhosis Drug Manufacturing Base Distribution, Product Types
3.4.1 Primary Biliary Cirrhosis Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Primary Biliary Cirrhosis Drug Product Type
3.4.3 Date of International Manufacturers Enter into Primary Biliary Cirrhosis Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
4.1.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2015-2020)
4.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2015-2020)
4.1.3 Primary Biliary Cirrhosis Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Primary Biliary Cirrhosis Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Primary Biliary Cirrhosis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Primary Biliary Cirrhosis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
5.1.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2015-2020)
5.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2015-2020)
5.1.3 Primary Biliary Cirrhosis Drug Price by Application (2015-2020)
5.2 Primary Biliary Cirrhosis Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Primary Biliary Cirrhosis Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Primary Biliary Cirrhosis Drug by Country
6.1.1 North America Primary Biliary Cirrhosis Drug Sales by Country
6.1.2 North America Primary Biliary Cirrhosis Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
6.3 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Primary Biliary Cirrhosis Drug by Country
7.1.1 Europe Primary Biliary Cirrhosis Drug Sales by Country
7.1.2 Europe Primary Biliary Cirrhosis Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
7.3 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Primary Biliary Cirrhosis Drug by Region
8.1.1 Asia Pacific Primary Biliary Cirrhosis Drug Sales by Region
8.1.2 Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
8.3 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Primary Biliary Cirrhosis Drug by Country
9.1.1 Latin America Primary Biliary Cirrhosis Drug Sales by Country
9.1.2 Latin America Primary Biliary Cirrhosis Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
9.3 Central & South America Primary Biliary Cirrhosis Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Primary Biliary Cirrhosis Drug by Country
10.1.1 Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country
10.1.2 Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Type
10.3 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Application
11 Company Profiles
11.1 AlbireoPharma
11.1.1 AlbireoPharma Corporation Information
11.1.2 AlbireoPharma Description and Business Overview
11.1.3 AlbireoPharma Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
11.1.5 AlbireoPharma Related Developments
11.2 CymaBay Therapeutics, Inc.
11.2.1 CymaBay Therapeutics, Inc. Corporation Information
11.2.2 CymaBay Therapeutics, Inc. Description and Business Overview
11.2.3 CymaBay Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Products Offered
11.2.5 CymaBay Therapeutics, Inc. Related Developments
11.3 Dr. Falk Pharma GmbH
11.3.1 Dr. Falk Pharma GmbH Corporation Information
11.3.2 Dr. Falk Pharma GmbH Description and Business Overview
11.3.3 Dr. Falk Pharma GmbH Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Products Offered
11.3.5 Dr. Falk Pharma GmbH Related Developments
11.4 Enanta Pharmaceuticals, Inc.
11.4.1 Enanta Pharmaceuticals, Inc. Corporation Information
11.4.2 Enanta Pharmaceuticals, Inc. Description and Business Overview
11.4.3 Enanta Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
11.4.5 Enanta Pharmaceuticals, Inc. Related Developments
11.5 GlaxoSmithKline Plc
11.5.1 GlaxoSmithKline Plc Corporation Information
11.5.2 GlaxoSmithKline Plc Description and Business Overview
11.5.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Products Offered
11.5.5 GlaxoSmithKline Plc Related Developments
11.6 Intercept Pharmaceuticals, Inc.
11.6.1 Intercept Pharmaceuticals, Inc. Corporation Information
11.6.2 Intercept Pharmaceuticals, Inc. Description and Business Overview
11.6.3 Intercept Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
11.6.5 Intercept Pharmaceuticals, Inc. Related Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Corporation Information
11.7.2 Johnson & Johnson Description and Business Overview
11.7.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Products Offered
11.7.5 Johnson & Johnson Related Developments
11.8 MediGene AG
11.8.1 MediGene AG Corporation Information
11.8.2 MediGene AG Description and Business Overview
11.8.3 MediGene AG Sales, Revenue and Gross Margin (2015-2020)
11.8.4 MediGene AG Primary Biliary Cirrhosis Drug Products Offered
11.8.5 MediGene AG Related Developments
11.9 NGM Biopharmaceuticals, Inc.
11.9.1 NGM Biopharmaceuticals, Inc. Corporation Information
11.9.2 NGM Biopharmaceuticals, Inc. Description and Business Overview
11.9.3 NGM Biopharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
11.9.5 NGM Biopharmaceuticals, Inc. Related Developments
11.10 Virobay Inc.
11.10.1 Virobay Inc. Corporation Information
11.10.2 Virobay Inc. Description and Business Overview
11.10.3 Virobay Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Virobay Inc. Primary Biliary Cirrhosis Drug Products Offered
11.10.5 Virobay Inc. Related Developments
11.1 AlbireoPharma
11.1.1 AlbireoPharma Corporation Information
11.1.2 AlbireoPharma Description and Business Overview
11.1.3 AlbireoPharma Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
11.1.5 AlbireoPharma Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Primary Biliary Cirrhosis Drug Market Estimates and Projections by Region
12.1.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Regions 2021-2026
12.2 North America Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.2.1 North America: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.2.2 North America: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.2.3 North America: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.3.2 Europe: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Primary Biliary Cirrhosis Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Primary Biliary Cirrhosis Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Primary Biliary Cirrhosis Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Primary Biliary Cirrhosis Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Primary Biliary Cirrhosis Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Primary Biliary Cirrhosis Drug Market Segments
Table 2. Ranking of Global Top Primary Biliary Cirrhosis Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Budesonide
Table 5. Major Manufacturers of FFP-104
Table 6. Major Manufacturers of GSK-2330672
Table 7. Major Manufacturers of MBX-8025
Table 8. Major Manufacturers of NGM-282
Table 9. Major Manufacturers of Others
Table 10. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Primary Biliary Cirrhosis Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Primary Biliary Cirrhosis Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Primary Biliary Cirrhosis Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Primary Biliary Cirrhosis Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Primary Biliary Cirrhosis Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Primary Biliary Cirrhosis Drug Sales Share by Manufacturers (2015-2020)
Table 17. Global Primary Biliary Cirrhosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Primary Biliary Cirrhosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Biliary Cirrhosis Drug as of 2019)
Table 19. Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Primary Biliary Cirrhosis Drug Price (2015-2020) (USD/Pcs)
Table 22. Primary Biliary Cirrhosis Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Primary Biliary Cirrhosis Drug Product Type
Table 24. Date of International Manufacturers Enter into Primary Biliary Cirrhosis Drug Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Primary Biliary Cirrhosis Drug Sales by Type (2015-2020) (K Pcs)
Table 27. Global Primary Biliary Cirrhosis Drug Sales Share by Type (2015-2020)
Table 28. Global Primary Biliary Cirrhosis Drug Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Primary Biliary Cirrhosis Drug Revenue Share by Type (2015-2020)
Table 30. Primary Biliary Cirrhosis Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Primary Biliary Cirrhosis Drug Sales by Application (2015-2020) (K Pcs)
Table 32. Global Primary Biliary Cirrhosis Drug Sales Share by Application (2015-2020)
Table 33. North America Primary Biliary Cirrhosis Drug Sales by Country (2015-2020) (K Pcs)
Table 34. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2015-2020)
Table 35. North America Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2015-2020)
Table 37. North America Primary Biliary Cirrhosis Drug Sales by Type (2015-2020) (K Pcs)
Table 38. North America Primary Biliary Cirrhosis Drug Sales Market Share by Type (2015-2020)
Table 39. North America Primary Biliary Cirrhosis Drug Sales by Application (2015-2020) (K Pcs)
Table 40. North America Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
Table 41. Europe Primary Biliary Cirrhosis Drug Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country (2015-2020)
Table 43. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2015-2020)
Table 45. Europe Primary Biliary Cirrhosis Drug Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Type (2015-2020)
Table 47. Europe Primary Biliary Cirrhosis Drug Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
Table 57. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2015-2020)
Table 61. Latin America Primary Biliary Cirrhosis Drug Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Primary Biliary Cirrhosis Drug Sales Market Share by Type (2015-2020)
Table 63. Latin America Primary Biliary Cirrhosis Drug Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
Table 73. AlbireoPharma Corporation Information
Table 74. AlbireoPharma Description and Major Businesses
Table 75. AlbireoPharma Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. AlbireoPharma Product
Table 77. AlbireoPharma Recent Development
Table 78. CymaBay Therapeutics, Inc. Corporation Information
Table 79. CymaBay Therapeutics, Inc. Description and Major Businesses
Table 80. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. CymaBay Therapeutics, Inc. Product
Table 82. CymaBay Therapeutics, Inc. Recent Development
Table 83. Dr. Falk Pharma GmbH Corporation Information
Table 84. Dr. Falk Pharma GmbH Description and Major Businesses
Table 85. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Dr. Falk Pharma GmbH Product
Table 87. Dr. Falk Pharma GmbH Recent Development
Table 88. Enanta Pharmaceuticals, Inc. Corporation Information
Table 89. Enanta Pharmaceuticals, Inc. Description and Major Businesses
Table 90. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Enanta Pharmaceuticals, Inc. Product
Table 92. Enanta Pharmaceuticals, Inc. Recent Development
Table 93. GlaxoSmithKline Plc Corporation Information
Table 94. GlaxoSmithKline Plc Description and Major Businesses
Table 95. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. GlaxoSmithKline Plc Product
Table 97. GlaxoSmithKline Plc Recent Development
Table 98. Intercept Pharmaceuticals, Inc. Corporation Information
Table 99. Intercept Pharmaceuticals, Inc. Description and Major Businesses
Table 100. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Intercept Pharmaceuticals, Inc. Product
Table 102. Intercept Pharmaceuticals, Inc. Recent Development
Table 103. Johnson & Johnson Corporation Information
Table 104. Johnson & Johnson Description and Major Businesses
Table 105. Johnson & Johnson Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Johnson & Johnson Product
Table 107. Johnson & Johnson Recent Development
Table 108. MediGene AG Corporation Information
Table 109. MediGene AG Description and Major Businesses
Table 110. MediGene AG Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. MediGene AG Product
Table 112. MediGene AG Recent Development
Table 113. NGM Biopharmaceuticals, Inc. Corporation Information
Table 114. NGM Biopharmaceuticals, Inc. Description and Major Businesses
Table 115. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. NGM Biopharmaceuticals, Inc. Product
Table 117. NGM Biopharmaceuticals, Inc. Recent Development
Table 118. Virobay Inc. Corporation Information
Table 119. Virobay Inc. Description and Major Businesses
Table 120. Virobay Inc. Primary Biliary Cirrhosis Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Virobay Inc. Product
Table 122. Virobay Inc. Recent Development
Table 123. Global Primary Biliary Cirrhosis Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 124. Global Primary Biliary Cirrhosis Drug Sales Market Share Forecast by Regions (2021-2026)
Table 125. Global Primary Biliary Cirrhosis Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 126. Global Primary Biliary Cirrhosis Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 127. North America: Primary Biliary Cirrhosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 128. North America: Primary Biliary Cirrhosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Europe: Primary Biliary Cirrhosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 130. Europe: Primary Biliary Cirrhosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 131. Asia Pacific: Primary Biliary Cirrhosis Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 132. Asia Pacific: Primary Biliary Cirrhosis Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 133. Latin America: Primary Biliary Cirrhosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 134. Latin America: Primary Biliary Cirrhosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Middle East and Africa: Primary Biliary Cirrhosis Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 136. Middle East and Africa: Primary Biliary Cirrhosis Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 137. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 138. Key Challenges
Table 139. Market Risks
Table 140. Main Points Interviewed from Key Primary Biliary Cirrhosis Drug Players
Table 141. Primary Biliary Cirrhosis Drug Customers List
Table 142. Primary Biliary Cirrhosis Drug Distributors List
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Biliary Cirrhosis Drug Product Picture
Figure 2. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Budesonide Product Picture
Figure 4. FFP-104 Product Picture
Figure 5. GSK-2330672 Product Picture
Figure 6. MBX-8025 Product Picture
Figure 7. NGM-282 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Primary Biliary Cirrhosis Drug Report Years Considered
Figure 14. Global Primary Biliary Cirrhosis Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Primary Biliary Cirrhosis Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Primary Biliary Cirrhosis Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region in 2019
Figure 19. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region in 2019
Figure 21. Global Primary Biliary Cirrhosis Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Primary Biliary Cirrhosis Drug Revenue in 2019
Figure 23. Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type in 2019
Figure 26. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type in 2019
Figure 28. Global Primary Biliary Cirrhosis Drug Market Share by Price Range (2015-2020)
Figure 29. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application in 2019
Figure 31. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application in 2019
Figure 33. North America Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country in 2019
Figure 36. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Primary Biliary Cirrhosis Drug Market Share by Type in 2019
Figure 42. North America Primary Biliary Cirrhosis Drug Market Share by Application in 2019
Figure 43. Europe Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country in 2019
Figure 46. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Country in 2019
Figure 47. Germany Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Primary Biliary Cirrhosis Drug Market Share by Type in 2019
Figure 58. Europe Primary Biliary Cirrhosis Drug Market Share by Application in 2019
Figure 59. Asia Pacific Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Market Share by Region in 2019
Figure 63. China Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Primary Biliary Cirrhosis Drug Market Share by Type in 2019
Figure 86. Asia Pacific Primary Biliary Cirrhosis Drug Market Share by Application in 2019
Figure 87. Latin America Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Primary Biliary Cirrhosis Drug Sales Market Share by Country in 2019
Figure 90. Latin America Primary Biliary Cirrhosis Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Primary Biliary Cirrhosis Drug Market Share by Type in 2019
Figure 98. Latin America Primary Biliary Cirrhosis Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Primary Biliary Cirrhosis Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Primary Biliary Cirrhosis Drug Market Share by Application in 2019
Figure 111. North America Primary Biliary Cirrhosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Primary Biliary Cirrhosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Primary Biliary Cirrhosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Primary Biliary Cirrhosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
肝硬変の世界市場（～2026年） Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. Alcohol has been identified as the strongest risk factor for liver cirrhosis. Market Analysis and Insights: Global Liver Cirrhosis Market The global Liver Cirrhosis …- 肝硬変治療薬の世界市場（～2026年） Market Analysis and Insights: Global Liver Cirrhosis Therapeutics Market The global Liver Cirrhosis Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Liver Cirrhosis Therapeutics Scope and Market Size Liver …
- 小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…
- 大麻薬の世界市場（～2026年） Drugs with chemicals taken directly from the marijuana plant，or with synthetic versions of chemicals naturally found in marijuana. Market Analysis and Insights: Global Cannabis Drug Market The global Cannabis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…
- 乱用薬物検査サービスの世界市場（～2026年） Drug of Abuse Testing Services is the use of testing services to avoid the negative effects of drug abuse, to reduce the accidents. In addition to rise in number of substance abusers and increase in number of government initiatives to avoid ill effects of substance abuse at workplace & reduce number…